Recent Development – AVT06 Settlement Secures U.S. Launch Timeline
Alvotech (NASDAQ: ALVO), a pure-play biosimilars company, announced a major breakthrough for its AVT06 biosimilar (a proposed version of Regeneron’s Eylea®). On December 19, 2025, Alvotech and its U.S. commercialization partner Teva reached a settlement and license agreement with Regeneron that grants a U.S. launch date for AVT06 in the fourth quarter of 2026, or earlier under certain circumstances ([1]) ([1]). This settlement resolves U.S. patent litigation around Eylea (aflibercept) and, pending FDA approval, positions Alvotech/Teva to enter the lucrative retinal disease market with a biosimilar to Eylea as soon as late 2026 ([1]). AVT06 is considered “game-changing” for Alvotech given Eylea’s multi-billion-dollar market – indeed, AVT06 has already secured marketing approvals in Europe, the UK and Japan ([1]), indicating a global opportunity once U.S. entry is allowed. Alvotech’s CEO noted this settlement “positions [them] very well for a successful launch in the U.S. market…pending FDA approval” ([1]).
Business Model & Pipeline Overview
Alvotech’s Strategy: Founded in 2013 and headquartered in Iceland, Alvotech focuses exclusively on developing and manufacturing biosimilars – lower-cost biologic medicines comparable to branded biologics ([2]). The company operates an integrated R&D and biologics manufacturing facility in Reykjavik and licenses its products to commercialization partners worldwide ([2]). In the U.S., Teva Pharmaceuticals is Alvotech’s strategic partner, with exclusive rights to commercialize multiple Alvotech biosimilar candidates (AVT02, AVT04, AVT05, AVT06, AVT16) under a long-term agreement ([3]). In Europe and other regions, partners like Germany’s Stada and Canada’s JAMP Pharma market Alvotech’s products ([3]) ([3]). This partnership model provides Alvotech milestone payments and profit-sharing from partners, allowing a global reach without building its own salesforce. For example, Advanz Pharma paid Alvotech $61 million upfront in 2023 for European rights to five pipeline biosimilars including AVT05 (Simponi) and AVT16 (Entyvio) ([4]).
Current Products: Alvotech has five biosimilars approved across various markets, with two major products launched to date ([2]). Its lead product AVT02 is a high-concentration, interchangeable biosimilar to AbbVie’s Humira® (adalimumab). AVT02 has regulatory approval in 55+ countries and has been launched in over 25 markets ([3]) ([3]). Notably, the FDA approved AVT02 in February 2024 as an interchangeable Humira biosimilar (meaning pharmacists can substitute it for Humira without prescriber intervention), and Alvotech/Teva launched AVT02 in the U.S. during the first half of 2024 ([3]). The second product, AVT04, is a biosimilar to J&J’s Stelara® (ustekinumab). AVT04 received FDA approval in April 2024 and was launched in Japan, Canada, and select EU countries in mid-2024 ([3]) ([3]); U.S. launch followed in February 2025 ([3]). Early traction is promising – management reported that the 2024 biosimilar launches (Humira in the U.S., Stelara globally) drove a 420% revenue surge in 2024 ([2]).
Pipeline Depth: Alvotech’s pipeline targets some of the largest biologic drugs facing patent expiry. Beyond AVT02 (Humira), AVT04 (Stelara), and AVT06 (Eylea), the company is developing biosimilars for Amgen’s Prolia®/Xgeva® (denosumab, “AVT03”), J&J’s Simponi® (golimumab, “AVT05”), Takeda’s Entyvio® (vedolizumab, “AVT16”), Novartis’ Xolair® (omalizumab, “AVT23”), and even Merck’s Keytruda® (pembrolizumab, “AVT33”), among others ([3]). In total, management discloses 12 biosimilar programs in development in addition to the five already approved, collectively targeting over $185 billion in branded drug sales ([2]). This aggressive pipeline reflects Alvotech’s ambition to be a leader in the coming “wave” of biosimilar opportunities as dozens of biologics lose exclusivity each year ([2]). However, execution will depend on both R&D success and regulatory compliance (as discussed later).
Dividend Policy & Yield
Dividend History: Alvotech is in growth mode and has never paid a dividend. In fact, the company explicitly states it does not anticipate paying cash dividends in the foreseeable future, choosing to reinvest any earnings into expanding its biosimilar business ([3]). This policy is evident in practice – no dividends were declared or paid in 2022, 2023, or 2024 ([3]). Alvotech’s shareholders thus should not expect income payouts; potential returns hinge on stock price appreciation driven by pipeline success.
AFFO/FFO: Metrics like FFO (Funds From Operations) or AFFO are not applicable here, as those are used for REITs/cash-yielding businesses. As a biotech manufacturer, Alvotech’s relevant cash flow metrics are operating cash flow and adjusted EBITDA. On that front, the company achieved positive EBITDA in 2024 for the first time and is guiding further EBITDA growth (see Valuation section) ([2]). But net income remains negative due to heavy interest and R&D expenses – Alvotech reported net losses of $552 million in 2023 and $232 million in 2024 ([3]), and it continues to accumulate a large deficit. Consequently, all cash is being plowed back into the business, and any notion of dividends is effectively off the table until the company matures and turns sustainably profitable ([3]) ([3]).
Leverage, Debt Maturities & Interest Coverage
Capital Structure: Alvotech has a high debt load arising from the financing needed to build its manufacturing platform. In mid-2024, the company refinanced its debt with a new $965 million Secured Loan Facility maturing July 2029 ([3]). This facility is structured in two parts: a first-lien $900 million term loan (SOFR + 6.5% interest) and a subordinated $65 million “second-out” tranche (SOFR + 10.5%) ([3]) ([3]). At December 31, 2024, Alvotech had $990.7 million outstanding under this facility plus $77.8 million of other bank loans (e.g. mortgages on its Reykjavik plant) ([3]) – roughly $1.07 billion total debt. In late 2025, Alvotech raised additional financing via $100 million of senior unsecured convertible bonds due 2030 (6.4–6.9% coupon) to bolster liquidity ([5]). Including this new convert, total debt now exceeds $1.1 billion, a significant levered position relative to the company’s ~$600 million annual revenue run-rate.
Double Guarantees. Zero Risk.
Interest Costs & Coverage: Servicing this debt is a major financial obligation. The secured term loan allowed Alvotech to capitalize (PIK) interest through June 30, 2025 to conserve cash ([3]), but as of mid-2025 the company must pay cash interest on the $900M first-lien loan (the $65M second tranche can still PIK interest) ([3]). With SOFR rates elevated, the cash interest rate is ~11–12% on the bulk of the loan (e.g. ~6.5% margin + ~5% SOFR). This implies annual interest expense on the term loan on the order of $100+ million, plus ~$6–7 million from the new convert bonds, and a few million on other bank debt – total interest likely $110–$120 million per year. By comparison, Alvotech’s adjusted EBITDA guidance for 2025 is $130–$150 million ([5]), suggesting interest coverage will be thin (~1.1×) in the near term. In the first nine months of 2025, Alvotech’s EBITDA margin was 16% ([2]), but this was before full interest payments kicked in. The CFO noted that starting Q3 2025, operating cash flow was impacted by cash outflows for inventory build and interest payments now being made on the loans ([2]). The bottom line: Alvotech’s coverage of interest is just barely above 1×, meaning essentially all operating profit is going toward debt service at present. This leveraged profile leaves little room for error or setbacks, making revenue growth and margin expansion critical going forward.
Debt Maturities: Encouragingly, Alvotech has no near-term maturities – the bulk of its debt is term-funded to mid/late 2029 ([3]), and the convert matures 2030 ([5]). The 2024 refinancing wiped out any 2025 maturities and pushed out the timeline, giving management breathing room to execute the pipeline. Quarterly amortization on the first-lien loan is minimal (0.25% of principal quarterly) ([3]). However, leverage remains high (Net Debt/EBITDA was >7× for 2024) and the company will need to either grow into its capital structure or eventually refinance again. Notably, the loan facility is secured by essentially all assets including IP ([3]) and carries restrictive covenants (limiting additional debt, dividends, asset sales, etc.) ([3]). Failure to meet obligations could put the company’s assets at risk of foreclosure ([3]), underscoring the importance of improving cash flows.
Valuation & Comparables
After a steep selloff in 2023–2024, Alvotech’s stock price recently trades around $5–6 per share**, down roughly 60% from a year ago ([6]). At ~$5.60/share, Alvotech’s market capitalization is about $1.5 billion ([6]). Including its $1.1B debt, the enterprise value (EV) is roughly $2.6 billion. How does this stack up against fundamentals? On a trailing basis, EV/revenue is high because 2024 sales were only ~$500M. But the market is clearly valuing Alvotech on its growth trajectory and pipeline potential. Using management’s guidance, 2025 revenue is expected to reach $570–$600 million with $130–$150 M adjusted EBITDA ([7]), and 2026 revenue $650–$700 M with $180–$220 M EBITDA ([7]). Based on these outlooks, Alvotech is trading at roughly 4.3× EV/2025 sales and ~12–14× EV/2026 EBITDA (at the midpoint of guidance). This valuation is not cheap in absolute terms, but it reflects the high growth (20%+ revenue CAGR) and improving profitability (targeting ~30% EBITDA growth in 2025) ([2]) ([2]). It’s also a premium to traditional generic drug companies, but more in line with biotech peers that have significant pipeline optionality.
Peer Comparison: Pure-play biosimilar peers are limited – many biosimilar developers are divisions of large pharma (e.g. Pfizer, Sandoz, Biocon) or smaller biotechs with narrower focus. One U.S.-traded peer, Coherus BioSciences (CHRS), shifted into biosimilars (with a Humira biosimilar launched in 2023), but Coherus is smaller and has struggled financially (market cap ~$150M). European peers like Formycon and Samsung Bioepis (via Biogen) also target similar molecules. Compared to these, Alvotech is differentiated by its vertically-integrated manufacturing and broad pipeline – more akin to a mini-Sandoz. Sandoz (spun out of Novartis in 2023) trades around ~1.5× sales as a mature generics business, but it has slower growth and lower margins than Alvotech’s projected profile. Thus, Alvotech’s valuation (EV ≈ 3.7× 2026E sales) can be seen as a bet on its future pipeline success and margin expansion rather than current earnings. Importantly, the stock’s slump indicates investor skepticism around execution: for instance, the recent $100M convertible bond deal involved lending of up to 20 million shares to bondholders (to facilitate short hedging), which can temporarily depress the share price through short-selling ([5]) ([5]). If Alvotech delivers on guidance and regulatory milestones, there may be significant upside from today’s levels – but the market is pricing in the substantial risks discussed below.
Risks & Red Flags
Regulatory and Manufacturing Risks: As with any biotech, FDA and EMA approvals are a gating factor for Alvotech’s products. A major red flag emerged in mid-2025 when the FDA conducted a compliance inspection of Alvotech’s Reykjavik manufacturing facility. The inspection found issues, leading to a Complete Response Letter (CRL) in Q4 2025 delaying U.S. approval of AVT05 (biosimilar to Simponi) ([2]). The sole reason for the CRL was unresolved manufacturing deficiencies at the plant ([2]). This indicates Alvotech’s facility is under close scrutiny; until those issues are fully resolved, U.S. approvals for pending biosimilars (like AVT03 denosumab) could be delayed. In fact, Alvotech has warned that it may receive a CRL for AVT03 as well, and its 2025–26 forecasts assume FDA approvals only by late 2026 for pending filings ([7]). Any prolonged FDA compliance problems would impair Alvotech’s ability to launch new products on schedule – a critical risk since its growth plan relies on a cadence of biosimilar approvals. The company must implement corrective actions at its plant and pass re-inspections to unlock U.S. licensures. Investors should watch for updates on the FDA’s stance (e.g. resolution of the Form 483 observations or warning letters, if any). Regulatory risk extends to intellectual property as well – while Alvotech has settled key patent disputes (Humira with AbbVie; Eylea with Regeneron) ([3]) ([1]), patent litigation could still arise for other pipeline drugs in certain jurisdictions, potentially delaying launches.
Commercial & Competitive Risks: Alvotech’s revenue growth depends on successfully penetrating markets with its partners. Competition in each biosimilar category is intense. For example, its Humira biosimilar (AVT02) entered a crowded U.S. field in 2024 – about 10 Humira biosimilars launched in the U.S. in 2023, triggering heavy price erosion. While interchangeability gives AVT02 a marketing edge, it still faces steep discounting and formulary battles. Similarly, biosimilars to Stelara and Eylea are being developed by multiple firms. Alvotech notes that competitors such as Amgen, Sandoz, Celltrion, Samsung, Biocon, and others are pursuing many of the same reference products (e.g. Stelara, Prolia, Eylea, etc.) ([3]) ([3]). Being first-to-market or obtaining interchangeability can confer advantage, but there is no guarantee Alvotech/Teva will capture significant market share if larger rivals undercut on price or if payers favor the originators’ defensive strategies (for instance, Regeneron’s introduction of a higher-dose Eylea formulation to protect its franchise). Another risk is partner execution – Alvotech relies on partners like Teva, Stada, and others to actually sell its products. Any misstep by a partner (e.g. slow uptake, weaker salesforce effort, or strategic deprioritization) could hurt Alvotech’s results ([3]). So far Teva appears committed (it invested $40M into Alvotech’s bonds and is actively launching products ([3])), but partner risk is inherent in the B2B model.
Financial & Liquidity Risks: Alvotech’s leveraged balance sheet is a double-edged sword. While the 2024 refinancing removed short-term default risk, the $1+ billion debt means high fixed costs (interest) and less flexibility. Should there be delays in revenue ramp (due to regulatory or commercial issues), the company might burn cash to pay interest and fund R&D, potentially forcing dilutive equity raises or additional debt. Indeed, in July 2023 Alvotech had to issue $140M of convertible bonds (subscribed by Teva and others) to bridge its funding ([4]), and again in late 2025 it issued $100M of new converts – clear signs that external capital has been needed to sustain operations. The company forecasts heavy R&D spending (~$250M in 2026) to advance its pipeline ([5]), on top of ongoing capex and working capital needs (building inventory for launches). While Alvotech ended Q3 2025 with ~$43M cash ([2]) (before the new bond funding), its cash buffer is limited relative to outflows. Any unforeseen setback – e.g. a product launch delay or a need to invest in facility upgrades – could necessitate further financing. This could dilute existing shareholders or add even more debt. Investors should note that as a Luxembourg-domiciled company, Alvotech has different insolvency and shareholder rights regimes than a typical U.S. firm. The secured lenders have strong collateral rights (including over Alvotech’s IP) ([3]), meaning equity holders would be severely impaired if the company ever faltered and debt holders exercised remedies. In sum, Alvotech’s financial risk profile is high: execution must be near-flawless to meet its debt obligations while funding growth.
Other Red Flags: – Negative Equity: Due to accumulated losses exceeding $2 billion since inception, Alvotech has a negative book equity position ([3]). While not uncommon for a young biotech, this underscores how heavily the company has been financed by debt and outside capital. – Share Overhang: The convertible bonds create an overhang of potential dilution (if converted to equity by 2030). In the recent $100M issue, a large block of shares was borrowed and sold short by bond investors (to hedge), which can impede stock price appreciation in the near term ([5]). – Key Person Risk: Chairman/CEO Róbert Wessman is the founder and driving force behind Alvotech. He has a strong track record in generics, but his outsized role means the company’s strategy execution is closely tied to his leadership. Any disruption or change at the top could be material.
Open Questions & Outlook
Despite the risks, Alvotech’s outlook holds considerable promise if key questions are resolved positively:
– Can Alvotech fix its FDA compliance issues in time? This is perhaps the most pressing question. Management insists the recent CRL did “not change the status” of its facility and that remediation is underway ([2]). The company must convince regulators that its manufacturing quality meets U.S. standards, ideally in 2026, to get pending BLAs (e.g. AVT03 denosumab) approved on schedule. Successful resolution would restore confidence; failure or protracted delays would cast doubt on the entire pipeline timeline.
– Will 2026 bring a breakthrough to positive cash flow? Alvotech’s 2026 guidance (>$180M EBITDA on ~$675M sales) ([7]) implies improving margins as more products (Stelara, Humira biosimilars) reach scale and new ones (perhaps Eylea in EU, etc.) launch. If achieved, this level of EBITDA would cover interest comfortably and start chipping away at net losses. However, the guidance already factors in some delays (it assumes U.S. approvals by late 2026) ([7]). Any upside surprises – for instance, earlier entry of AVT06 in the U.S. if certain conditions allow before Q4 2026 ([1]) – could boost 2026 numbers. Conversely, if competition or pricing is harsher than expected, hitting those targets will be challenging. An open question is how much market share and pricing power Alvotech (and Teva) can secure, especially in the U.S. Humira biosimilar market in 2025–26 and the Stelara market newly opening in 2025. Early indications show Alvotech’s products are gaining formulary coverage (e.g. AVT04 was among the top three Stelara biosims on the U.S. market in Q3 2025, per management) but quantifying share is difficult ([2]).
– Is the pipeline value being fully appreciated? With a dozen biosimilars in development, Alvotech has multiple shots on goal. Notably, AVT16 (Entyvio) and AVT23 (Xolair) are progressing, and AVT33 (Keytruda) is a bold long-term project targeting one of the world’s top-selling drugs ([3]). If Alvotech can successfully develop a Keytruda biosimilar for launch post-2028, it would be transformative – but this will require significant investment and likely a partner for the oncology market. There are open questions on whether Alvotech can fund these later-stage programs internally or will seek additional alliances (similar to how it partnered with Teva and Stada for earlier products). The company has shown it can attract partners (Teva, Stada, Fuji, Advanz, etc.), so one might expect future partnering deals that bring in cash (upfronts and milestones) for late-stage pipeline assets. Such deals could mitigate financing needs.
– How will the competitive landscape play out? Over 2025–2027, several key biologics see biosimilar competition (Stelara in 2025, Eylea ~2025-27, Entyvio 2026-27, etc.). A question for Alvotech is whether it can differentiate itself among biosimilar players – perhaps via cost-efficient manufacturing or being first-to-file in certain markets. Alvotech touts its integrated platform and pure-focus on biosimilars as an edge ([2]) ([2]). If this translates to consistently being among the first wave of biosimilars (as seen with Humira and Stelara) and reliable supply, it could secure a durable position in the industry. However, some rivals are much larger (e.g. Sandoz, Biocon, Amgen) with deeper pockets. It remains to be seen if a standalone biosimilar specialist can thrive long-term or if it becomes an acquisition target once it proves its pipeline. Given Alvotech’s heavy investment (>$2B to date) ([2]), one open question is whether a larger pharma might attempt to acquire the company to obtain its pipeline and biologics plant – particularly if the stock remains undervalued. For now, management seems intent on remaining independent and “leading the charge” in biosimilars ([2]).
Outlook: In summary, Alvotech is at a pivotal stage. The settlement for AVT06’s U.S. entry in 2026 is a significant de-risking event for one of its most important programs ([1]). By 2026, Alvotech could have 3–4 major products on the U.S. market (Humira, Stelara, Simponi, Eylea) and several in Europe/Global, driving substantial revenue growth. The company expects ~20% top-line growth in 2025 and an acceleration in 2026 as these launches compound ([2]) ([5]). Achieving these targets would go a long way to validating the business model. However, investors will likely remain cautious until Alvotech demonstrates clear progress on FDA compliance and self-funding ability. In the coming 12–18 months, watch for milestones such as: FDA re-inspection results, U.S. approval of AVT02’s interchangeability for additional indications, potential approval of AVT03 (denosumab) if the facility issues resolve, the actual market uptake of AVT04 (Stelara) as it rolls out in the U.S., and any new partnership deals (for pipeline or regional markets). Each of these will inform whether Alvotech can manage its high debt while executing a broad pipeline. If it can thread that needle, ALVO’s beaten-down stock could rerate significantly. If not, the company’s leverage and cash burn could become a more pressing concern. Thus, ALVO presents a high-risk, high-reward profile: settlement of the Eylea timeline is a positive step, but the game-changing potential of AVT06 – and indeed Alvotech’s whole platform – will only be realized if the company navigates the risks ahead with discipline and success.
Sources: Alvotech/Teva press releases ([1]) ([1]); Alvotech SEC 20-F ([3]) ([3]) and Q3’25 earnings call ([2]) ([2]); Investor presentation & 6-K guidance ([7]) ([5]); SEC filings on debt ([3]) ([3]); and credible financial media (GlobeNewswire, Yahoo Finance) ([1]) ([6]).
Sources
- https://globenewswire.com/news-release/2025/12/19/3208320/0/en/Alvotech-and-Teva-Secure-U-S-Settlement-Date-for-AVT06-a-Proposed-Biosimilar-to-Eylea.html
- https://fintool.com/app/research/companies/ALVO/documents/transcripts/q3-2025
- https://sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm
- https://investors.alvotech.com/news-releases/news-release-details/alvotech-reports-financial-results-first-six-months-2023-and
- https://stocktitan.net/news/ALVO/alvotech-launches-100-million-senior-unsecured-convertible-bond-3or2zfrywc7n.html
- https://companiesmarketcap.com/alvotech/marketcap/
- https://stocktitan.net/sec-filings/ALVO/6-k-alvotech-current-report-foreign-issuer-3b90abde8ddb.html
For informational purposes only; not investment advice.